CN115645425B - Paeonol-glycyrrhizic acid solid dispersion with synergistic antibacterial effect, and preparation method and application thereof - Google Patents
Paeonol-glycyrrhizic acid solid dispersion with synergistic antibacterial effect, and preparation method and application thereof Download PDFInfo
- Publication number
- CN115645425B CN115645425B CN202211437425.XA CN202211437425A CN115645425B CN 115645425 B CN115645425 B CN 115645425B CN 202211437425 A CN202211437425 A CN 202211437425A CN 115645425 B CN115645425 B CN 115645425B
- Authority
- CN
- China
- Prior art keywords
- paeonol
- glycyrrhizic acid
- solid dispersion
- preparation
- acid solid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229960004949 glycyrrhizic acid Drugs 0.000 title claims abstract description 98
- 239000001685 glycyrrhizic acid Substances 0.000 title claims abstract description 98
- 239000007962 solid dispersion Substances 0.000 title claims abstract description 71
- 230000000844 anti-bacterial effect Effects 0.000 title claims abstract description 31
- 238000002360 preparation method Methods 0.000 title claims abstract description 24
- 230000002195 synergetic effect Effects 0.000 title claims abstract description 22
- UILPJVPSNHJFIK-UHFFFAOYSA-N Paeonol Chemical compound COC1=CC=C(C(C)=O)C(O)=C1 UILPJVPSNHJFIK-UHFFFAOYSA-N 0.000 claims abstract description 148
- YLTGFGDODHXMFB-UHFFFAOYSA-N isoacetovanillon Natural products COC1=CC=C(C(C)=O)C=C1O YLTGFGDODHXMFB-UHFFFAOYSA-N 0.000 claims abstract description 74
- MLIBGOFSXXWRIY-UHFFFAOYSA-N paeonol Natural products COC1=CC=C(O)C(C(C)=O)=C1 MLIBGOFSXXWRIY-UHFFFAOYSA-N 0.000 claims abstract description 74
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 claims abstract description 53
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 claims abstract description 53
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 claims abstract description 53
- 235000019410 glycyrrhizin Nutrition 0.000 claims abstract description 53
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims abstract description 50
- 239000003814 drug Substances 0.000 claims abstract description 33
- 239000000203 mixture Substances 0.000 claims abstract description 7
- 238000000034 method Methods 0.000 claims description 22
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 21
- 229940079593 drug Drugs 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 12
- 241000191967 Staphylococcus aureus Species 0.000 claims description 12
- 239000002904 solvent Substances 0.000 claims description 11
- 239000003242 anti bacterial agent Substances 0.000 claims description 6
- 238000000935 solvent evaporation Methods 0.000 claims description 6
- 241000186427 Cutibacterium acnes Species 0.000 claims description 5
- 241000588747 Klebsiella pneumoniae Species 0.000 claims description 5
- 229940055019 propionibacterium acne Drugs 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 239000002674 ointment Substances 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 239000012046 mixed solvent Substances 0.000 claims 2
- 229940124350 antibacterial drug Drugs 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 238000004090 dissolution Methods 0.000 abstract description 12
- 239000004480 active ingredient Substances 0.000 abstract description 6
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 244000000010 microbial pathogen Species 0.000 abstract 1
- 229940126680 traditional chinese medicines Drugs 0.000 abstract 1
- 238000002156 mixing Methods 0.000 description 12
- 238000005303 weighing Methods 0.000 description 11
- 230000000694 effects Effects 0.000 description 8
- 238000000227 grinding Methods 0.000 description 8
- 238000007873 sieving Methods 0.000 description 8
- 239000000022 bacteriostatic agent Substances 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 239000006069 physical mixture Substances 0.000 description 6
- 238000010298 pulverizing process Methods 0.000 description 6
- 239000012747 synergistic agent Substances 0.000 description 6
- 201000004624 Dermatitis Diseases 0.000 description 5
- -1 glycyrrhizic acid diamine Chemical class 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- VVOAZFWZEDHOOU-UHFFFAOYSA-N magnolol Chemical compound OC1=CC=C(CC=C)C=C1C1=CC(CC=C)=CC=C1O VVOAZFWZEDHOOU-UHFFFAOYSA-N 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- MCMNRKCIXSYSNV-UHFFFAOYSA-N Zirconium dioxide Chemical compound O=[Zr]=O MCMNRKCIXSYSNV-UHFFFAOYSA-N 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical group C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- ILRKKHJEINIICQ-OOFFSTKBSA-N Monoammonium glycyrrhizinate Chemical compound N.O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O ILRKKHJEINIICQ-OOFFSTKBSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 208000010668 atopic eczema Diseases 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000002131 composite material Substances 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 229930014626 natural product Natural products 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 2
- JOOXCMJARBKPKM-UHFFFAOYSA-N 4-oxopentanoic acid Chemical compound CC(=O)CCC(O)=O JOOXCMJARBKPKM-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 239000008118 PEG 6000 Substances 0.000 description 2
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 2
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- FUWUEFKEXZQKKA-UHFFFAOYSA-N beta-thujaplicin Chemical compound CC(C)C=1C=CC=C(O)C(=O)C=1 FUWUEFKEXZQKKA-UHFFFAOYSA-N 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 229940109262 curcumin Drugs 0.000 description 2
- 235000012754 curcumin Nutrition 0.000 description 2
- 239000004148 curcumin Substances 0.000 description 2
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 229940074774 glycyrrhizinate Drugs 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
- 229960000502 poloxamer Drugs 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000007928 solubilization Effects 0.000 description 2
- 238000005063 solubilization Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- KJPRLNWUNMBNBZ-QPJJXVBHSA-N (E)-cinnamaldehyde Chemical compound O=C\C=C\C1=CC=CC=C1 KJPRLNWUNMBNBZ-QPJJXVBHSA-N 0.000 description 1
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- VWDXGKUTGQJJHJ-UHFFFAOYSA-N Catenarin Natural products C1=C(O)C=C2C(=O)C3=C(O)C(C)=CC(O)=C3C(=O)C2=C1O VWDXGKUTGQJJHJ-UHFFFAOYSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 239000010282 Emodin Substances 0.000 description 1
- RBLJKYCRSCQLRP-UHFFFAOYSA-N Emodin-dianthron Natural products O=C1C2=CC(C)=CC(O)=C2C(=O)C2=C1CC(=O)C=C2O RBLJKYCRSCQLRP-UHFFFAOYSA-N 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- 240000004670 Glycyrrhiza echinata Species 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- YOOXNSPYGCZLAX-UHFFFAOYSA-N Helminthosporin Natural products C1=CC(O)=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O YOOXNSPYGCZLAX-UHFFFAOYSA-N 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- BYTORXDZJWWIKR-UHFFFAOYSA-N Hinokiol Natural products CC(C)c1cc2CCC3C(C)(CO)C(O)CCC3(C)c2cc1O BYTORXDZJWWIKR-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- NTGIIKCGBNGQAR-UHFFFAOYSA-N Rheoemodin Natural products C1=C(O)C=C2C(=O)C3=CC(O)=CC(O)=C3C(=O)C2=C1O NTGIIKCGBNGQAR-UHFFFAOYSA-N 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 241000863480 Vinca Species 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- TUFYVOCKVJOUIR-UHFFFAOYSA-N alpha-Thujaplicin Natural products CC(C)C=1C=CC=CC(=O)C=1O TUFYVOCKVJOUIR-UHFFFAOYSA-N 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- QDWKGBODFCIIJK-IHMBCTQLSA-N azanium;(2s,4as,6ar,6as,6br,8ar,10s,12as,14br)-10-hydroxy-2,4a,6a,6b,9,9,12a-heptamethyl-13-oxo-3,4,5,6,6a,7,8,8a,10,11,12,14b-dodecahydro-1h-picene-2-carboxylate Chemical compound [NH4+].C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C([O-])=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C QDWKGBODFCIIJK-IHMBCTQLSA-N 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229940117916 cinnamic aldehyde Drugs 0.000 description 1
- KJPRLNWUNMBNBZ-UHFFFAOYSA-N cinnamic aldehyde Natural products O=CC=CC1=CC=CC=C1 KJPRLNWUNMBNBZ-UHFFFAOYSA-N 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000010227 cup method (microbiological evaluation) Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000012738 dissolution medium Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000009982 effect on human Effects 0.000 description 1
- RHMXXJGYXNZAPX-UHFFFAOYSA-N emodin Chemical compound C1=C(O)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O RHMXXJGYXNZAPX-UHFFFAOYSA-N 0.000 description 1
- VASFLQKDXBAWEL-UHFFFAOYSA-N emodin Natural products OC1=C(OC2=C(C=CC(=C2C1=O)O)O)C1=CC=C(C=C1)O VASFLQKDXBAWEL-UHFFFAOYSA-N 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- FVYXIJYOAGAUQK-UHFFFAOYSA-N honokiol Chemical compound C1=C(CC=C)C(O)=CC=C1C1=CC(CC=C)=CC=C1O FVYXIJYOAGAUQK-UHFFFAOYSA-N 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 229940088592 immunologic factor Drugs 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000009878 intermolecular interaction Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 229940040102 levulinic acid Drugs 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229940095102 methyl benzoate Drugs 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 239000002539 nanocarrier Substances 0.000 description 1
- 239000007908 nanoemulsion Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- PKUBGLYEOAJPEG-UHFFFAOYSA-N physcion Natural products C1=C(C)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O PKUBGLYEOAJPEG-UHFFFAOYSA-N 0.000 description 1
- 229960002292 piperacillin Drugs 0.000 description 1
- WCMIIGXFCMNQDS-IDYPWDAWSA-M piperacillin sodium Chemical compound [Na+].O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC=CC=1)C(=O)N[C@@H]1C(=O)N2[C@@H](C([O-])=O)C(C)(C)S[C@@H]21 WCMIIGXFCMNQDS-IDYPWDAWSA-M 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000001144 powder X-ray diffraction data Methods 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 229930007845 β-thujaplicin Natural products 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
The invention provides a medicine-medicine solid dispersion prepared from paeonol and glycyrrhizic acid serving as active ingredients of traditional Chinese medicines, which has excellent synergistic antibacterial effect on various pathogenic microorganisms and is simple and convenient to prepare. The solid dispersion prepared by the invention has the antibacterial effect obviously superior to that of each single medicine component and the mixture thereof, and the solubility and the dissolution of the paeonol component are obviously improved, thereby being beneficial to further preparation forming and improving the bioavailability.
Description
Technical Field
The invention relates to the technical field of medicines, in particular to a paeonol-glycyrrhizic acid solid dispersion with a synergistic antibacterial effect, a preparation method of the paeonol-glycyrrhizic acid solid dispersion and application of the paeonol-glycyrrhizic acid solid dispersion in preparation of antibacterial medicines.
Background
In recent years, the abuse of antibiotics has led to the generation of drug-resistant bacteria, severely affecting the clinical therapeutic effect. Meanwhile, natural products with antibacterial activity are gradually discovered, so that the natural products are not easy to generate drug resistance, and have the advantages of multiple activities, multiple targets, low toxicity and the like. At present, researchers have proposed strategies for combining natural products with antibiotics in order to achieve the problems of weakening bacterial resistance, reducing antibiotic residues and the like. The invention selects two traditional Chinese medicine active ingredients with a certain antibacterial effect, namely paeonol and glycyrrhizic acid, and the paeonol and the glycyrrhizic acid are processed into an amorphous medicine-medicine solid dispersion, so that the synergistic antibacterial effect obviously superior to that of the original medicine is obtained.
Paeonol (PAE) is a small molecular phenolic compound extracted from root bark of Paeonol or dried root of radix Cynanchi Paniculati, and has low melting point, high volatility, slight solubility in water, and low oral bioavailability; in addition, paeonol has poor stability, and the preparation is easy to crystallize. The paeonol is taken orally to treat cardiovascular diseases, and is made into ointment for treating skin inflammation, eczema, etc. Modern researches have shown that paeonol itself has strong inhibiting effect on colibacillus, staphylococcus aureus, typhoid bacillus and the like.
Glycyrrhizic acid (Glycyrrhizic acid, GL) is the most important active ingredient of traditional Chinese medicine licorice, and consists of two molecules of glucuronic acid and one molecule of glycyrrhetinic acid. In clinical application, glycyrrhizic acid can be used for treating liver injury, chronic viral hepatitis, etc., and can be used for treating skin diseases such as inflammation by external application. Modern researches have shown that glycyrrhizic acid has definite pharmacological actions such as antibacterial and anti-inflammatory.
The pharmacy generally utilizes novel preparation technologies such as nano carriers, inclusion compounds, microcapsules, solid dispersions and the like to improve the solubility of insoluble drugs or improve the stability of the drugs. The technology generally needs to add a large amount of carriers or auxiliary materials to form, or involves a complex process method and has lower yield.
The prior art CN113545994A discloses a plant source composite bacteriostatic agent for the cosmetic field and application thereof, wherein the plant source composite bacteriostatic agent comprises the following raw materials in percentage by mass: 1-30% of bacteriostat, 0.5-50% of synergistic agent and 20-98.5% of solvent; the bacteriostatic agent is one or two of cinnamaldehyde and paeonol, and the synergistic agent is one or more of benzalkonium chloride, magnolol, honokiol, hinokitiol, glycyrrhizic acid and its salt, citric acid and its salt, etc. The plant source composite bacteriostatic agent is safe and effective, has the effects of resisting bacteria, relieving itching and resisting sensitization, can be used as an antibacterial and antiallergic active ingredient to be applied to skin care cosmetics, and has good safety and no toxic or side effect on human bodies. However, firstly, the effect of glycyrrhizic acid in the prior art is only speculative, no verification or theoretical explanation is made on the technical effect of glycyrrhizic acid, only the specific scheme of methyl benzoate, levulinic acid and caryophyllin as a synergistic agent is given in the specification, the technical scheme of specific combination of paeonol and glycyrrhizic acid is not given, and secondly, although part of chemical substances are named as the synergistic agent in the prior art, no evidence proves that the synergistic agent can produce synergistic effect with bacteriostatic agents such as paeonol, and the description of paragraphs 41-42 of the specification shows that in fact, only superposition of bacteriostatic effect is generated between the bacteriostatic agent and the synergistic agent, and no synergistic effect is generated. Moreover, the prior art described above does not give any technical teaching for preparing solid dispersions. In summary, the above prior art does not provide a technical scheme that paeonol and glycyrrhizic acid are specifically combined into a solid dispersion, and does not provide a technical suggestion that paeonol and glycyrrhizic acid have a synergistic effect.
The prior art TW200633691A discloses an enhancer for enhancing the antibiotic activity of antibiotics, wherein the enhancer can be curcumin, emodin, glycyrrhizic acid, magnolol, paeonol and the like, and specifically provides a technical scheme of taking curcumin as a piperacillin enhancer. However, the above prior art does not suggest that the combination of glycyrrhizic acid and paeonol can produce an antibacterial synergistic effect.
The prior art (development of paeonol oral medicine film) (Liu Chanming, etc., chinese patent medicine, 8 th 1992) discloses a preparation process of paeonol oral medicine film, which comprises the steps of taking PVA film-forming material, adding proper distilled water and glycerin, heating in water bath for dissolution, filtering, and preserving heat at 75 ℃ for 15min; and adding paeonol, monoammonium glycyrrhizinate and tween-80, heating in water bath until paeonol is melted, rapidly taking down, grinding, adding above matrix, stirring while adding distilled water to adjust volume, and defoaming. The medicine directly contacts with the affected part, is absorbed by mucous membrane, exerts the anti-inflammatory and analgesic effects, can avoid the first pass effect of liver, and greatly reduces the dosage. However, monoammonium glycyrrhetate is used in the prior art, instead of glycyrrhizic acid; in addition, the prior art does not show the proportion of paeonol to monoammonium glycyrrhizinate, and does not show what technical effect is produced after monoammonium glycyrrhizinate is added.
The prior art (the combined application research of the glycyrrhizic acid diamine and the paeonol) (Luo Xin and the like, the university of vinca and traditional Chinese medicine report, 24 (6), and 12 months in 2008) discloses that the glycyrrhizic acid diamine can play a role in treating eczema dermatitis by controlling inflammatory factors and immune factors, and the paeonol has the effects of easing pain, calming and hypnotizing, resisting inflammation, relieving fever, resisting allergy, enhancing immune functions and the like. The clinical combined application of the two has obvious curative effect on acute eczema. The specific treatment method comprises 1 time/d of glycyrrhizic acid diamine (ganlixin), 40mL intravenous drip each time, and topical application of paeonol ointment. 15 d is 1 course of treatment. However, the paeonol and the diamine glycyrrhizinate are administered by different routes, the diamine glycyrrhizinate is administered by injection, and paeonol is administered topically, and no composition or solid dispersion is formed, and the use thereof is not for producing a synergistic antibacterial effect.
The medicine-medicine solid dispersion is based on intermolecular interaction between paeonol and glycyrrhizic acid, does not need to add any carrier or auxiliary materials, and has simple process and stable product.
Disclosure of Invention
The invention aims to provide paeonol-glycyrrhizic acid solid dispersion with a synergistic antibacterial effect. The solid dispersion can reduce the cost and the administration dosage under the condition of meeting the antibacterial requirement, or can enhance the antibacterial effect under the condition of the same administration dosage.
Another object of the present invention is to provide a solid dispersion which can improve dissolution, absorption and permeation properties of paeonol, can improve stability of paeonol and can inhibit crystallization of paeonol, and can be prepared simply without adding any functional auxiliary materials.
It is another object of the present invention to provide a method for preparing the above solid dispersion.
The invention also aims to provide the application of the solid dispersion in preparing medicines, namely, the solid dispersion is used as a preparation intermediate to be further prepared into various oral or external antibacterial preparations such as gel, tablets, capsules and the like, so that the solid dispersion is convenient for clinical application.
Specifically, the invention provides the following technical scheme:
a solid dispersion with synergistic antibacterial effect comprises paeonol and glycyrrhizic acid as active ingredients of traditional Chinese medicine, wherein no functional auxiliary material is added, and the molar ratio of paeonol to glycyrrhizic acid is 1:10-10:1.
Preferably, the molar ratio of paeonol to glycyrrhizic acid is in the range of 1:5-5:1.
More preferably, the molar ratio of paeonol to glycyrrhizic acid is in the range of 1:3-3:1.
Most preferably, the molar ratio of paeonol to glycyrrhizic acid is 1:1.
The invention also provides a method for preparing the solid dispersion, namely a solvent evaporation method, a grinding method and a melting method. Preferably, the preparation method is a solvent evaporation method.
The solvent evaporation method is to weigh a proper amount of paeonol and glycyrrhizic acid, completely dissolve in the solvent, uniformly mix, naturally volatilize the solvent at room temperature, and crush to obtain paeonol-glycyrrhizic acid solid dispersion. Preferred solvents are ethanol and methanol.
The grinding method comprises weighing paeonol and appropriate amount of glycyrrhizic acid, placing in beaker, adding appropriate amount of zirconia beads with appropriate size, grinding for 3 hr, and sieving with 80 mesh sieve to obtain paeonol-glycyrrhizic acid solid dispersion.
The melting method comprises weighing paeonol and appropriate amount of glycyrrhizic acid, heating glycyrrhizic acid to molten state, cooling to a certain temperature, adding paeonol, mixing, rapidly solidifying in ice bath, pulverizing, and sieving with 80 mesh sieve to obtain paeonol-glycyrrhizic acid solid dispersion.
The inventor verifies through experiments that the solid dispersion obtained by the solvent evaporation method has the highest product yield, the preparation process is simple, and the obtained product has the best synergistic antibacterial effect.
Preferably, the solid dispersion of the invention has obvious synergistic antibacterial effect on klebsiella pneumoniae, staphylococcus aureus, drug-resistant staphylococcus aureus and propionibacterium acnes.
The solid dispersion obtained by the invention is in an amorphous form, and is more stable than paeonol raw material medicines, better in dissolution performance and higher in dissolution rate. Without limitation, the inventors believe that the above-described effect of increasing stability and solubility may be related in part to the reason that glycyrrhizic acid can self-assemble in water to form micelles, and can improve the solubility and bioavailability of other poorly soluble molecules by solubilization or the like. However, it should be noted that the above solubilization may not be related to the synergistic antibacterial effect between glycyrrhizic acid and paeonol, because experiments by the inventor prove that other ways of increasing the solubility of paeonol, such as using other surfactants or nanoemulsions, are adopted in combination with other common antibacterial agents other than glycyrrhizic acid, and the antibacterial effect is also significantly worse than that of paeonol-glycyrrhizic acid pharmaceutical compositions under the same conditions, and no synergistic effect is generated.
The paeonol-glycyrrhizic acid solid dispersion provided by the invention is simple to prepare, low in cost and good in reproducibility.
The invention takes the solid dispersion as a preparation intermediate, further prepares a plurality of preparations, and is prepared from the solid dispersion and pharmaceutic adjuvant.
In summary, the inventors have found through unexpected studies that the preparation of a solid dispersion by mixing the components of paeonol and glycyrrhizic acid can produce a remarkable synergistic antibacterial effect, which is significantly greater than that of paeonol or glycyrrhizic acid alone, and also greater than that of a simple mixture of paeonol and glycyrrhizic acid. Besides, the solubility and bioavailability of the active ingredients can be obviously increased, and the stability is obviously enhanced. In addition, any auxiliary materials are not needed in the process of preparing the solid dispersion, so that the cost is saved.
Description of the drawings:
FIG. 1 is a graph of paeonol-glycyrrhizic acid solid dispersion PXRD and stability test results in example 1; wherein A is a solid dispersion PXRD pattern; b is a stability diagram.
FIG. 2 is a graph showing the equilibrium solubility and in vitro dissolution of paeonol-glycyrrhizic acid solid dispersion according to example 1; wherein a is an equilibrium solubility profile (< 0.05 compared to bulk drug group; (< 0.05 compared to physical mixture group); b is an in vitro dissolution profile (mean±sd; n=3).
The following description of the embodiments of the present invention will be made clearly and completely with reference to the accompanying drawings, in which it is evident that the embodiments described are only some embodiments of the present invention, but not all embodiments.
Detailed Description
Example 1: weighing appropriate amount of paeonol and glycyrrhizic acid (molar ratio of 1:1), completely dissolving in methanol, mixing, naturally volatilizing solvent at room temperature, and pulverizing to obtain paeonol-glycyrrhizic acid solid dispersion.
Example 2: weighing appropriate amount of paeonol and glycyrrhizic acid (molar ratio of 1:10), respectively dissolving in 70% ethanol, mixing, concentrating at 40deg.C under reduced pressure, naturally volatilizing at room temperature, pulverizing, sieving to obtain paeonol-glycyrrhizic acid solid dispersion, adding appropriate amount of starch, mixing, dry granulating, and directly encapsulating to obtain paeonol-glycyrrhizic acid capsule.
Example 3: weighing appropriate amount of paeonol and glycyrrhizic acid (molar ratio of 10:1), completely dissolving in methanol, mixing, concentrating at 40deg.C under reduced pressure, naturally volatilizing at room temperature, pulverizing, sieving to obtain paeonol-glycyrrhizic acid solid dispersion, adding appropriate amount of microcrystalline cellulose, mixing, and directly encapsulating to obtain paeonol-glycyrrhizic acid capsule.
Example 4: weighing appropriate amount of paeonol and glycyrrhizic acid (molar ratio of 1:5), respectively dissolving in 70% ethanol, mixing, concentrating at 45deg.C under reduced pressure, naturally volatilizing at room temperature, pulverizing, sieving to obtain paeonol-glycyrrhizic acid solid dispersion, adding appropriate amount of starch, mixing, and directly tabletting to obtain paeonol-glycyrrhizic acid tablet.
Example 5: weighing a proper amount of paeonol and glycyrrhizic acid (the molar ratio is 5:1), completely dissolving in methanol, uniformly mixing, naturally volatilizing the solvent at room temperature, and pulverizing to obtain paeonol-glycyrrhizic acid solid dispersion; weighing a proper amount of the composition, dissolving in a proper amount of water, adding a proper amount of hydroxypropyl methylcellulose for dispersion, fully swelling and uniformly mixing to obtain paeonol-glycyrrhizic acid gel.
Example 6: weighing a proper amount of paeonol and glycyrrhizic acid (the molar ratio is 1:3), firstly heating glycyrrhizic acid to a molten state in a water bath kettle at 80 ℃, cooling to about 40 ℃, adding paeonol, stirring for 5min to uniformly mix, placing in an ice bath to rapidly solidify after uniformly mixing, crushing and sieving with a 80-mesh sieve to obtain the paeonol-glycyrrhizic acid solid dispersion.
Example 7: weighing a proper amount of paeonol and glycyrrhizic acid (the molar ratio is 3:1), placing into a beaker, adding a proper amount of zirconia beads with proper size, grinding for 3 hours together, and sieving with a 80-mesh sieve to obtain the paeonol-glycyrrhizic acid solid dispersion.
Example 8: weighing a proper amount of paeonol and glycyrrhizic acid (the molar ratio is 1:1), placing into a mortar, adding a proper amount of methanol, grinding for 1h, naturally volatilizing the solvent at room temperature, crushing and sieving with a 80-mesh sieve to obtain paeonol-glycyrrhizic acid solid dispersion, adding a proper amount of hydroxypropyl methylcellulose into 95% ethanol, uniformly stirring, uniformly spreading on a smooth glass plate, placing into a 40 ℃ oven, drying for 2 h, and removing to obtain the paeonol-glycyrrhizic acid oral instant film.
Example 9: paeonol-glycyrrhizic acid in-vitro medicine combination antibacterial effect test
MIC was measured by microdilution, and concentration of Klebsiella pneumoniae, staphylococcus aureus, drug-resistant Staphylococcus aureus, and Propionibacterium acnes was adjusted to 3×10 5 Inoculating CFU/mL into 96-well sterile culture plate, adding appropriate amount of paeonol and glycyrrhizic acid in table 1, changing their ratio, solid dispersion prepared from paeonol and common solid dispersion carrier (polyethylene glycol PEG6000 or poloxamer F68) and physical mixture of paeonol and glycyrrhizic acid or different adjuvants,dissolving in DMSO, diluting with each time, adding into the bacterial suspension, and respectively setting negative control and positive control. Culturing in a constant temperature incubator at 37 ℃ for 18-24 h, observing growth conditions, adding 10 mu L of prepared TTC solution, continuously culturing in the incubator at 37 ℃ for 2 h under the dark condition, observing dyeing change, and obtaining the MIC of the medicine which is the lowest medicine concentration group without being dyed red.
MBC was measured by streaking, inoculating a bacterial culture solution of a MIC experiment 96-well plate, which was not subjected to bacterial growth, to a solid medium, culturing in a constant temperature incubator at 37℃for 16-18 hours, observing the results, counting colonies, and performing parallel operation 3 times on each bacterium with a minimum concentration of drug of less than 5 colonies as MBC of the bacterium.
Table 1 MIC and MBC values (mg/mL) for each group of samples against Staphylococcus aureus
Table 1 shows that the MIC and MBC values of paeonol-glycyrrhizic acid solid dispersions prepared under different molar ratios are significantly lower than those of the two raw material medicaments and the physical mixture thereof, and the paeonol-glycyrrhizic acid solid dispersions show excellent synergistic antibacterial effect; wherein the MIC of the solid dispersion obtained in the molar ratio of 1:1 is less than 0.46 mg/mL, the MBC is less than 0.73 mg/mL, and the synergistic antibacterial effect is optimal; under the condition of the same fixed molar ratio of the two medicines, the paeonol-glycyrrhizic acid solid dispersion prepared by adopting the solvent volatilization method has an antibacterial effect which is obviously better than that of a sample prepared by adopting the grinding method, and the MIC and MBC values of the paeonol-glycyrrhizic acid solid dispersion are respectively 4.8 and 6.0 times of those of the paeonol-glycyrrhizic acid solid dispersion prepared by adopting the grinding method; the weight ratio of paeonol to carrier is basically consistent with that of paeonol to glycyrrhizic acid (molar ratio 1:1) by adopting a solvent volatilization method respectively to prepare two solid dispersions of polyethylene glycol PEG 6000\poloxamer F68, but the MIC value is about 10 times different, and the antibacterial effect of the two solid dispersions is almost consistent with that of a physical mixture, so that the improvement of the dissolution performance of the solid dispersions on paeonol is not a key factor of the paeonol-glycyrrhizic acid solid dispersions in playing a synergistic antibacterial effect.
TABLE 2 MIC (mg/mL) of each group of sample concentrations for different bacterial solutions
Table 2 shows that the combination of paeonol and glycyrrhizic acid shows excellent synergistic antibacterial effect against Klebsiella pneumoniae, staphylococcus aureus, drug resistant Staphylococcus aureus and Propionibacterium acnes.
Example 10: characterization of paeonol-glycyrrhizic acid solid dispersion properties
The appropriate amount of the solid dispersion obtained in example 1 was scanned by a powder X-ray diffractometer (PXRD) under the following measurement conditions: the scanning angle is 2 theta, the step length is 0.02 DEG, the scanning speed is 8 DEG/min, and the scanning range is 3-85 deg. The results are shown in FIG. 1A.
FIG. 1A shows that the characteristic peak of the product formed in Experimental example 1 disappears, and is in an amorphous form, i.e., paeonol-glycyrrhizic acid amorphous solid dispersion.
Example 11: paeonol equilibrium solubility determination
In the embodiment of the invention, the solubility test of paeonol-glycyrrhizic acid solid dispersion is referred to the edition 2020 of Chinese pharmacopoeia: taking excessive paeonol raw material, solid dispersion and physical mixture with different proportions, placing into a constant temperature gas bath table (37 ℃ C., 100 r/min), shaking 72 h, taking out, immediately centrifuging, taking out supernatant, passing through a 0.22 μm microporous filter membrane, measuring the absorption peak area by HPLC, and calculating the equilibrium solubility of paeonol, wherein the result is shown in figure 2A.
Fig. 2A shows that the solid dispersion prepared in example 1 has significantly improved paeonol solubility, and the solubility increases as the paeonol ratio decreases.
Example 12: evaluation of paeonol in vitro dissolution Performance
The dissolution rate of the paeonol-glycyrrhizic acid solid dispersion in the embodiment of the invention is referred to a small cup method of the 2020 edition of Chinese pharmacopoeia: the release medium was water at a temperature of 37.+ -. 0.5 ℃ and a small amount of paeonol and a considerable amount of the physical mixture and solid dispersion (example 1) were accurately weighed in a 250mL beaker, 2mL was sampled and passed through a 0.22 μm microporous filter membrane while supplementing an isothermal equal volume of the dissolution medium, the absorption peak area thereof was measured by HPLC, the cumulative dissolution for each time period was calculated, and the dissolution curve was drawn, and the results are shown in fig. 2B.
Figure 2B shows that the in vitro release rates of paeonol and glycyrrhizic acid are significantly faster.
While the foregoing description illustrates and describes the preferred embodiments of the present invention, it is to be understood that the invention is not limited to the forms disclosed herein, but is not to be construed as limited to other embodiments, and is capable of numerous other combinations, modifications and environments and is capable of changes or modifications within the scope of the inventive concept as described herein, either as a result of the foregoing teachings or as a result of the knowledge or technology in the relevant art. And that modifications and variations which do not depart from the spirit and scope of the invention are intended to be within the scope of the appended claims.
Claims (7)
1. A paeonol-glycyrrhizic acid solid dispersion with synergistic antibacterial effect is characterized in that: the paeonol-glycyrrhizic acid composition comprises paeonol and glycyrrhizic acid, wherein the molar ratio of paeonol to glycyrrhizic acid is 1:1-1:5; the preparation method is a solvent evaporation method, and the solvent used in the preparation process is ethanol, methanol or a mixed solvent containing water;
the antibacterial agent is used for inhibiting or killing staphylococcus aureus, drug-resistant staphylococcus aureus, klebsiella pneumoniae and/or propionibacterium acnes.
2. The paeonol-glycyrrhizic acid solid dispersion according to claim 1, characterized in that: the molar ratio of paeonol to glycyrrhizic acid is 1:1-1:3.
3. The paeonol-glycyrrhizic acid solid dispersion according to claim 2, characterized in that: the molar ratio of paeonol to glycyrrhizic acid is 1:1.
4. The paeonol-glycyrrhizic acid solid dispersion according to claim 1, characterized in that: the paeonol-glycyrrhizic acid solid dispersion is in an amorphous state, and has no characteristic diffraction peak under the detection of a powder X-ray diffractometer.
5. A method for preparing paeonol-glycyrrhizic acid solid dispersion according to claim 1, characterized in that:
the preparation method is a solvent evaporation method, and the solvent used in the preparation process is ethanol, methanol or a mixed solvent containing water.
6. Use of the paeonol-glycyrrhizic acid solid dispersion according to claim 1 for the preparation of an antibacterial drug, characterized in that: the antibacterial agent is used for inhibiting or killing staphylococcus aureus, drug-resistant staphylococcus aureus, klebsiella pneumoniae and/or propionibacterium acnes.
7. Use according to claim 6, characterized in that: the medicine is an oral preparation
Or external preparation, wherein the oral preparation is tablet, capsule, granule, powder or oral liquid,
the external preparation is a solution, gel, patch or ointment.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211437425.XA CN115645425B (en) | 2022-11-17 | 2022-11-17 | Paeonol-glycyrrhizic acid solid dispersion with synergistic antibacterial effect, and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211437425.XA CN115645425B (en) | 2022-11-17 | 2022-11-17 | Paeonol-glycyrrhizic acid solid dispersion with synergistic antibacterial effect, and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115645425A CN115645425A (en) | 2023-01-31 |
| CN115645425B true CN115645425B (en) | 2024-02-20 |
Family
ID=85020071
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211437425.XA Active CN115645425B (en) | 2022-11-17 | 2022-11-17 | Paeonol-glycyrrhizic acid solid dispersion with synergistic antibacterial effect, and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115645425B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002363091A (en) * | 2001-06-08 | 2002-12-18 | Noevir Co Ltd | Skin care preparation |
| KR20030043520A (en) * | 2001-11-28 | 2003-06-02 | 주식회사 엘지생활건강 | Oral compositions against halitosis |
| CN113545994A (en) * | 2021-06-16 | 2021-10-26 | 广州艾卓生物科技股份有限公司 | Plant source composite bacteriostatic agent and application thereof |
-
2022
- 2022-11-17 CN CN202211437425.XA patent/CN115645425B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002363091A (en) * | 2001-06-08 | 2002-12-18 | Noevir Co Ltd | Skin care preparation |
| KR20030043520A (en) * | 2001-11-28 | 2003-06-02 | 주식회사 엘지생활건강 | Oral compositions against halitosis |
| CN113545994A (en) * | 2021-06-16 | 2021-10-26 | 广州艾卓生物科技股份有限公司 | Plant source composite bacteriostatic agent and application thereof |
Non-Patent Citations (3)
| Title |
|---|
| 丹皮酚口腔药膜的研制;刘产明等;中成药;第14卷(第08期);第8-9页 * |
| 丹皮酚软膏联合复方甘草酸苷治疗变应性接触性皮炎临床观察;杨正生等;陕西医学杂志;第40卷(第08期);第1069-1070页 * |
| 甘草酸二胺与丹皮酚联合应用研究;罗昕等;长春中医药大学学报;第24卷(第06期);第665-666页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115645425A (en) | 2023-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zainal-Abidin et al. | Emerging frontiers of deep eutectic solvents in drug discovery and drug delivery systems | |
| Nagula et al. | Cellulose microsponges based gel of naringenin for atopic dermatitis: Design, optimization, in vitro and in vivo investigation | |
| CN112010849A (en) | Flavonoid glycoside and isoquinoline alkaloid complex for inhibiting multiple drug-resistant staphylococcus aureus and preparation of carrier-free nano-drug thereof | |
| Pagano et al. | Development of sodium carboxymethyl cellulose based polymeric microparticles for in situ hydrogel wound dressing formation | |
| CN103193772A (en) | Preparation method and application of substituted aryl propionic berberine ion-pair compound | |
| Ahmed | Formulation and clinical investigation of optimized vinpocetine lyoplant-tabs: new strategy in development of buccal solid dosage form | |
| Han et al. | Surfactant-free amorphous solid dispersion with high dissolution for bioavailability enhancement of hydrophobic drugs: a case of quercetin | |
| Zhou et al. | Solubilization of luteolin in PVP40 solid dispersion improves inflammation-induced insulin resistance in mice | |
| CN115645425B (en) | Paeonol-glycyrrhizic acid solid dispersion with synergistic antibacterial effect, and preparation method and application thereof | |
| Wang et al. | Development and characterization of an amorphous curcumin-Eudragit® E100 solid dispersions with improved solubility, stability, and pharmacokinetic properties | |
| CN112209988A (en) | Tea sapogenin thiosemicarbazone zinc complex and preparation method and application thereof | |
| CN102743369A (en) | N-acetylcysteine pharmaceutical composition and preparation method thereof | |
| CN100502850C (en) | Medicinal composition of total capsicine compounds and beta-cyclodextrin or derivative of beta-cyclodextrin | |
| CN1919339B (en) | Cucurbitacin nano preparation comprising protein, preparation method and use thereof | |
| PL151121B1 (en) | Primycine-containing colloidal basic gel, process for its preparation and pharmaceutical or pharmaco-cosmetic compositions containing the basic gel | |
| Li et al. | Multicomponent self-assembly based on bioactive molecules of traditional Chinese medicine (TCM) | |
| CN107961320B (en) | Pharmaceutical composition for treating acute pancreatitis and preparation method thereof | |
| CN113214207B (en) | Hesperetin and betaine eutectic A, preparation method, composition and application thereof | |
| CN101032476A (en) | Medical combination including rhein or diacetylrhein and the preparing method thereof | |
| ES2955521T3 (en) | Procedure for dispersing adapalene in a gel preparation | |
| CN111440086A (en) | Salt of tranilast | |
| CN112830923A (en) | Serial cinnamic acid-isoquinoline alkaloid complex with selective antibacterial action and preparation of carrier-free nano-medicine thereof | |
| TWM468314U (en) | Dropping pill of antrodia cinnamomea | |
| CN1298347C (en) | Paste preparation for treating oxide lichen and its preparation technology | |
| US11834428B2 (en) | Dihydromyricetin nanocrystals and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |